×
About 69,910 results

ALLMedicine™ Colitis Center

Research & Reviews  32,667 results

Active uptake of 68Ga-FAPI in Crohn's disease but not in ulcerative colitis.
https://doi.org/10.1007/s00259-020-05129-7
European Journal of Nuclear Medicine and Molecular Imaging; Luo Y, Pan Q et. al.

Nov 28th, 2020 - Active uptake of 68Ga-FAPI in Crohn's disease but not in ulcerative colitis.|2020|Luo Y,Pan Q,Xu H,Zhang R,Li J,|

Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantat...
https://doi.org/10.1186/s12876-020-01548-w
BMC Gastroenterology; Dang XF, Qing-Xi Wang et. al.

Nov 27th, 2020 - Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), the pathogenesis of which is complicated, and it is difficult to treat. In recent years, the emerging fecal microbiota transplantation (FMT) has shown good effects in UC treatm...

Women's earnings are more affected by inflammatory bowel disease than men's: a register...
https://doi.org/10.1093/ecco-jcc/jjaa238
Journal of Crohn's & Colitis; Everhov ÅH, Bruze G et. al.

Nov 27th, 2020 - Patients with inflammatory bowel disease (IBD) have more work disability than the general population. We aimed to estimate the monetary cost of IBD for the individual through assessment of earnings in relation to diagnosis. Through linkage of nati...

Tissue exposure does not explain non-response in ulcerative colitis patients with adequ...
https://doi.org/10.1093/ecco-jcc/jjaa239
Journal of Crohn's & Colitis; Van den Berghe N, Verstockt B et. al.

Nov 27th, 2020 - Some patients with ulcerative colitis (UC) do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non...

Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placeb...
https://doi.org/10.1080/14787210.2021.1856656
Expert Review of Anti-infective Therapy; Mishra S, Mandavdhare HS et. al.

Nov 27th, 2020 - To evaluate the use of a combination of antibiotics as an adjuvant therapy in acute severe ulcerative colitis (ASUC). Patients with ASUC were randomized to either infusions of placebo or intravenous ceftriaxone and metronidazole in addition to sta...

see more →

Guidelines  115 results

AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor...
https://doi.org/10.1053/j.gastro.2020.08.063
Gastroenterology Dougan M, Wang Y et. al.

Oct 20th, 2020 - Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve ...

Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcera...
https://doi.org/10.1053/j.gastro.2020.03.011
Gastroenterology

Mar 28th, 2020 - Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.|2020| ,|

Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.
https://doi.org/10.1053/j.gastro.2020.03.012
Gastroenterology Feuerstein JD, Isaacs KL et. al.

Mar 14th, 2020 - Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Col...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175923
Gastroenterology Feuerstein JD, Isaacs KL et. al.

Jan 16th, 2020 - AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|therapeutic use,standards,diagnosis,immunology,therapy,diagnostic imaging,immunology,p...

ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
https://doi.org/10.1093/ecco-jcc/jjz187
Journal of Crohn's & Colitis; Adamina M, Bonovas S et. al.

Nov 19th, 2019 - This article is the second in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present art...

see more →

Drugs  825 results see all →

Clinicaltrials.gov  34,581 results

Active uptake of 68Ga-FAPI in Crohn's disease but not in ulcerative colitis.
https://doi.org/10.1007/s00259-020-05129-7
European Journal of Nuclear Medicine and Molecular Imaging; Luo Y, Pan Q et. al.

Nov 28th, 2020 - Active uptake of 68Ga-FAPI in Crohn's disease but not in ulcerative colitis.|2020|Luo Y,Pan Q,Xu H,Zhang R,Li J,|

Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantat...
https://doi.org/10.1186/s12876-020-01548-w
BMC Gastroenterology; Dang XF, Qing-Xi Wang et. al.

Nov 27th, 2020 - Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), the pathogenesis of which is complicated, and it is difficult to treat. In recent years, the emerging fecal microbiota transplantation (FMT) has shown good effects in UC treatm...

Women's earnings are more affected by inflammatory bowel disease than men's: a register...
https://doi.org/10.1093/ecco-jcc/jjaa238
Journal of Crohn's & Colitis; Everhov ÅH, Bruze G et. al.

Nov 27th, 2020 - Patients with inflammatory bowel disease (IBD) have more work disability than the general population. We aimed to estimate the monetary cost of IBD for the individual through assessment of earnings in relation to diagnosis. Through linkage of nati...

Tissue exposure does not explain non-response in ulcerative colitis patients with adequ...
https://doi.org/10.1093/ecco-jcc/jjaa239
Journal of Crohn's & Colitis; Van den Berghe N, Verstockt B et. al.

Nov 27th, 2020 - Some patients with ulcerative colitis (UC) do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non...

Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placeb...
https://doi.org/10.1080/14787210.2021.1856656
Expert Review of Anti-infective Therapy; Mishra S, Mandavdhare HS et. al.

Nov 27th, 2020 - To evaluate the use of a combination of antibiotics as an adjuvant therapy in acute severe ulcerative colitis (ASUC). Patients with ASUC were randomized to either infusions of placebo or intravenous ceftriaxone and metronidazole in addition to sta...

see more →

News  1,611 results

Ulcerative Colitis: Persistence and Colectomy-free Survival With Golimumab vs Adalimumab
https://www.medscape.com/viewarticle/941486

Nov 23rd, 2020 - Takeaway The persistence rates of antitumour necrosis factor agents golimumab and adalimumab as first-line or second-line biologic therapy for ulcerative colitis (UC) were above 64.0% at 12 months following treatment initiation. In addition, the 1...

Tool Predicted Vedolizumab Nonresponse in Routine Practice
https://www.medscape.com/viewarticle/940931

Nov 12th, 2020 - Among patients with ulcerative colitis who were treated in routine practice, a point-based clinical scoring tool predicted nonresponse to vedolizumab therapy, according to study findings published online in Clinical Gastroenterology and Hepatology...

Tool Predicted Vedolizumab Nonresponse in Routine Practice
https://www.staging.medscape.com/viewarticle/940931

Nov 12th, 2020 - Among patients with ulcerative colitis who were treated in routine practice, a point-based clinical scoring tool predicted nonresponse to vedolizumab therapy, according to study findings published online in Clinical Gastroenterology and Hepatology...

IBD Immunosuppressives Appears Safe During Pandemic
https://www.staging.medscape.com/viewarticle/940615

Nov 9th, 2020 - (Reuters) - People with inflammatory bowel disease (IBD) do not increase their risk for COVID-19 by taking immunosuppressive drugs to control their symptoms, according to a study of more than 5,300 patients with Crohn's disease or ulcerative colit...

IBD Immunosuppressives Appears Safe During Pandemic
https://www.medscape.com/viewarticle/940615

Nov 9th, 2020 - (Reuters) - People with inflammatory bowel disease (IBD) do not increase their risk for COVID-19 by taking immunosuppressive drugs to control their symptoms, according to a study of more than 5,300 patients with Crohn's disease or ulcerative colit...

see more →

Patient Education  111 results see all →